Zyuds Lifesciences receives USFDA approval for DMD treatment drug

Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Jaythari (Deflazacort) tablets.

“Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older,” the ompany said.

The drug maker will produce Jaythari (Deflazacort) 6 mg, 18 mg, 30 mg and 36 mg tablets at Doppel Farmaceutici S.r.l., Italy facility, Zydus said in a regulatory filing.